Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: a pooled analysis of PULSAR and STELLAR
Background - This analysis examined the effects of the activin signaling inhibitor, sotatercept, in pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). - Methods - Pooled data from PULSAR (N=106; NCT03496207) and STELLAR (N=323; NCT04576988) were analyzed using...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2025
|
| In: |
The journal of heart and lung transplantation
Year: 2025, Jahrgang: 44, Heft: 4, Pages: 609-624 |
| ISSN: | 1557-3117 |
| DOI: | 10.1016/j.healun.2024.11.037 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.healun.2024.11.037 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1053249824020096 
|
| Verfasserangaben: | Mardi Gomberg-Maitland, David B. Badesch, J. Simon R. Gibbs, Ekkehard Grünig, Marius M. Hoeper, Marc Humbert, Grzegorz Kopeć, Vallerie V. McLaughlin, Gisela Meyer, Karen M. Olsson, Ioana R. Preston, Stephan Rosenkranz, Rogerio Souza, Aaron B. Waxman, Loïc Perchenet, James Strait, Aiwen Xing, Amy O. Johnson-Levonas, Alexandra G. Cornell, Janethe de Oliveira Pena, and H. Ardeschir Ghofrani |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1941253547 | ||
| 003 | DE-627 | ||
| 005 | 20251120193731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251114s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.healun.2024.11.037 |2 doi | |
| 035 | |a (DE-627)1941253547 | ||
| 035 | |a (DE-599)KXP1941253547 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gomberg-Maitland, Mardi |e VerfasserIn |0 (DE-588)143345753 |0 (DE-627)704460548 |0 (DE-576)336565674 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension |b a pooled analysis of PULSAR and STELLAR |c Mardi Gomberg-Maitland, David B. Badesch, J. Simon R. Gibbs, Ekkehard Grünig, Marius M. Hoeper, Marc Humbert, Grzegorz Kopeć, Vallerie V. McLaughlin, Gisela Meyer, Karen M. Olsson, Ioana R. Preston, Stephan Rosenkranz, Rogerio Souza, Aaron B. Waxman, Loïc Perchenet, James Strait, Aiwen Xing, Amy O. Johnson-Levonas, Alexandra G. Cornell, Janethe de Oliveira Pena, and H. Ardeschir Ghofrani |
| 264 | 1 | |c April 2025 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.11.2025 | ||
| 520 | |a Background - This analysis examined the effects of the activin signaling inhibitor, sotatercept, in pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). - Methods - Pooled data from PULSAR (N=106; NCT03496207) and STELLAR (N=323; NCT04576988) were analyzed using 2 different CI thresholds, <2.0 and ≥2.0liter/min/m2 as well as <2.5 and≥2.5 liter/min/m2. Median changes from baseline at week 24 were evaluated using Hodges-Lehmann estimator and least squares (LS) means, with 95% confidence intervals and p-values (significance: p=0.05). Categorial endpoints and time-to-clinical worsening were analyzed by Cochran-Mantel-Haenszel and Cox model respectively. - Results - Of 429 participants, 51 had CI <2.0 and 378 ≥2.0liter/min/m2, while 179 had CI <2.5 and 250 ≥2.5liter/min/m2. Sotatercept significantly improved median 6-minute walk distance (range: 33.9 to 63.7m: p<0.001), pulmonary vascular resistance (range: −202.8 to −395.4 dyn•s•cm−5; p≤0.002), and N-terminal pro-B-type natriuretic peptide (range: −317.3 to −1,041.2pg/ml; p<0.001) across subgroups. LS means showed reductions in pulmonary and right atrial pressures, decreased right ventricular size, and improved tricuspid annular plane systolic excursion/systolic pulmonary artery pressure. Sotatercept delayed time to first occurrence of death or a worsening event for CI ≥2.5 (hazard ratio [HR] 0.12; p<0.001), ≥2.0 (HR 0.13; p<0.001), and <2.5 (HR 0.21; p<0.001) liter/min/m2. Improvements were observed in WHO functional class (all p<0.050) and ESC/ERS risk scores (all p<0.001). - Conclusions - Sotatercept demonstrated consistent efficacy and safety across CI subgroups, supporting its use in PAH patients irrespective of baseline cardiac hemodynamics. | ||
| 650 | 4 | |a cardiac index | |
| 650 | 4 | |a cardiac output | |
| 650 | 4 | |a hemodynamics | |
| 650 | 4 | |a pulmonary arterial hypertension | |
| 650 | 4 | |a sotatercept | |
| 700 | 1 | |a Badesch, David B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gibbs, J. Simon R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grünig, Ekkehard |e VerfasserIn |0 (DE-588)112535801 |0 (DE-627)618892605 |0 (DE-576)31856694X |4 aut | |
| 700 | 1 | |a Hoeper, Marius M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Humbert, Marc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kopeć, Grzegorz |e VerfasserIn |4 aut | |
| 700 | 1 | |a McLaughlin, Vallerie V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meyer, Gisela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Olsson, Karen M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Preston, Ioana R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rosenkranz, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Souza, Rogerio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Waxman, Aaron B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perchenet, Loïc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Strait, James |e VerfasserIn |4 aut | |
| 700 | 1 | |a Xing, Aiwen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Johnson-Levonas, Amy O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cornell, Alexandra G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Oliveira Pena, Janethe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ardeschir Ghofrani, H. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of heart and lung transplantation |d Amsterdam [u.a.] : Elsevier Science, 1999 |g 44(2025), 4 vom: Apr., Seite 609-624 |h Online-Ressource |w (DE-627)306659743 |w (DE-600)1500494-6 |w (DE-576)260773786 |x 1557-3117 |7 nnas |a Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension a pooled analysis of PULSAR and STELLAR |
| 773 | 1 | 8 | |g volume:44 |g year:2025 |g number:4 |g month:04 |g pages:609-624 |g extent:16 |a Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension a pooled analysis of PULSAR and STELLAR |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.healun.2024.11.037 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1053249824020096 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251114 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 112535801 |a Grünig, Ekkehard |m 112535801:Grünig, Ekkehard |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PG112535801 |e 950000PG112535801 |e 950900PG112535801 |e 50000PG112535801 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1941253547 |e 4805989106 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Mardi Gomberg-Maitland, David B. Badesch, J. Simon R. Gibbs, Ekkehard Grünig, Marius M. Hoeper, Marc Humbert, Grzegorz Kopeć, Vallerie V. McLaughlin, Gisela Meyer, Karen M. Olsson, Ioana R. Preston, Stephan Rosenkranz, Rogerio Souza, Aaron B. Waxman, Loïc Perchenet, James Strait, Aiwen Xing, Amy O. Johnson-Levonas, Alexandra G. Cornell, Janethe de Oliveira Pena, and H. Ardeschir Ghofrani"]},"note":["Gesehen am 14.11.2025"],"recId":"1941253547","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"April 2025"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1016/j.healun.2024.11.037"],"eki":["1941253547"]},"language":["eng"],"person":[{"given":"Mardi","display":"Gomberg-Maitland, Mardi","family":"Gomberg-Maitland","role":"aut"},{"role":"aut","given":"David B.","display":"Badesch, David B.","family":"Badesch"},{"role":"aut","given":"J. Simon R.","family":"Gibbs","display":"Gibbs, J. Simon R."},{"role":"aut","display":"Grünig, Ekkehard","family":"Grünig","given":"Ekkehard"},{"role":"aut","family":"Hoeper","display":"Hoeper, Marius M.","given":"Marius M."},{"given":"Marc","display":"Humbert, Marc","family":"Humbert","role":"aut"},{"given":"Grzegorz","display":"Kopeć, Grzegorz","family":"Kopeć","role":"aut"},{"role":"aut","display":"McLaughlin, Vallerie V.","family":"McLaughlin","given":"Vallerie V."},{"family":"Meyer","display":"Meyer, Gisela","given":"Gisela","role":"aut"},{"family":"Olsson","display":"Olsson, Karen M.","given":"Karen M.","role":"aut"},{"role":"aut","given":"Ioana R.","display":"Preston, Ioana R.","family":"Preston"},{"role":"aut","given":"Stephan","display":"Rosenkranz, Stephan","family":"Rosenkranz"},{"role":"aut","given":"Rogerio","display":"Souza, Rogerio","family":"Souza"},{"given":"Aaron B.","display":"Waxman, Aaron B.","family":"Waxman","role":"aut"},{"display":"Perchenet, Loïc","family":"Perchenet","given":"Loïc","role":"aut"},{"role":"aut","family":"Strait","display":"Strait, James","given":"James"},{"display":"Xing, Aiwen","family":"Xing","given":"Aiwen","role":"aut"},{"given":"Amy O.","family":"Johnson-Levonas","display":"Johnson-Levonas, Amy O.","role":"aut"},{"role":"aut","given":"Alexandra G.","display":"Cornell, Alexandra G.","family":"Cornell"},{"given":"Janethe","display":"de Oliveira Pena, Janethe","family":"de Oliveira Pena","role":"aut"},{"display":"Ardeschir Ghofrani, H.","family":"Ardeschir Ghofrani","given":"H.","role":"aut"}],"physDesc":[{"extent":"16 S."}],"title":[{"title":"Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension","subtitle":"a pooled analysis of PULSAR and STELLAR","title_sort":"Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"journal of heart and lung transplantation","subtitle":"a forum that includes basic science, the failing heart, and advanced lung disease ; the official publication of the International Society for Heart and Lung Transplantation","title":"The journal of heart and lung transplantation"}],"part":{"volume":"44","pages":"609-624","text":"44(2025), 4 vom: Apr., Seite 609-624","year":"2025","extent":"16","issue":"4"},"language":["eng"],"id":{"eki":["306659743"],"issn":["1557-3117"],"zdb":["1500494-6"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"Elsevier Science","dateIssuedDisp":"[1999?]-","publisherPlace":"Amsterdam [u.a.]"}],"recId":"306659743","pubHistory":["Nachgewiesen 18.1999 -"],"note":["Gesehen am 15.01.20","Ungezählte Beil.: Supplement"],"disp":"Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension a pooled analysis of PULSAR and STELLARThe journal of heart and lung transplantation"}]} | ||
| SRT | |a GOMBERGMAIEFFICACYAN2025 | ||